Skip to content
Screener

Idexx Laboratories IDXX Allowance for Doubtful Accounts Receivable (Current)

Allowance for Doubtful Accounts Receivable (Current) at other companies

Zoetis logo
ZoetisZTS
$14M-17.6%
Danaher logo
DanaherDHR
$121M+0.8%
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
$4.9M-37.2%
Abbott logo
AbbottABT
$486M+73.6%
Merck & Co. logo
Merck & Co.MRK
$108M+14.9%
Labcorp Holdings logo
Labcorp HoldingsLH
$33M-14.5%

Other financials

Income statement

See full
Revenue$1.2B+9.7%
Gross profit$779.1M+12.1%
Operating income$425.6M+14.1%
Net income$338.4M+15.1%
EPS (diluted)$4.27+17.6%

Balance sheet

See full
Cash & equivalents$196.9M+19.6%
Total debt$449.9M-31.7%
Total equity$1.6B+10.5%
Total assets$3.4B+3.3%

Cash flow

See full
Operating cash flow$347.2M+86.9%
CapEx$24.6M-27.7%
Free cash flow$322.5M+113%

Valuation

See full
Market cap$46.93B-10.0%
Enterprise value$47.19B-10.4%
P/E41.2×-11.7×
P/S10.3×-2.6×

Profitability

See full
Gross margin62.4%+0.9pp
Operating margin32%+0.9pp
Net margin25%+0.6pp
FCF margin27.5%+8.1pp

Returns & leverage

See full
Return on equity74.2%+9.3pp
Debt / equity0.3×-0.2×
Current ratio1.2×+0.1×

Where this comes from

Reported directly by Idexx Laboratories in its filing.

Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivable.

The source filing: Idexx Laboratories’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:14 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000874716-26-000076

The allowance for credit losses associated with accounts receivable was $14.3 million and $11.3 million as of March 31, 2026, and December 31, 2025, respectively. The amount of accounts receivable reflected on the balance sheet is net of this allowance. As of March 31, 2026, approximately 88% of our accounts receivable had not yet reached the invoice due date and approximately 12% were considered past due. As of December 31, 2025, approximately 87% of our accounts receivable had not yet reached the invoice due date and approximately 13% were considered past due.

Item 1. Financial Statements (unaudited)

FAQ

What is Idexx Laboratories's allowance for doubtful accounts receivable (current)?
Idexx Laboratories (IDXX) reported allowance for doubtful accounts receivable (current) of $14.3M in Q1 2026.
How has Idexx Laboratories's allowance for doubtful accounts receivable (current) changed year-over-year?
Idexx Laboratories's allowance for doubtful accounts receivable (current) increased by 12.6% year-over-year, from $12.7M to $14.3M.
What is the long-term trend for Idexx Laboratories's allowance for doubtful accounts receivable (current)?
Over 5 years (2020 to 2025), Idexx Laboratories's allowance for doubtful accounts receivable (current) has grown at a 10.7% compound annual growth rate (CAGR), from $6.8M to $11.3M.
What does allowance for doubtful accounts receivable (current) mean?
This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.

Ask your AI about Idexx Laboratories's allowance for doubtful accounts receivable (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude